ABNX.PA Stock - ABIONYX Pharma S.A.
Unlock GoAI Insights for ABNX.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.60M | $4.64M | $5.25M | $675,000 | N/A |
| Gross Profit | $844,000 | $618,000 | $636,000 | $259,000 | $-80,000 |
| Gross Margin | 18.3% | 13.3% | 12.1% | 38.4% | N/A |
| Operating Income | $-5,572,000 | $-3,412,000 | $-4,109,000 | $-5,952,000 | $-3,585,000 |
| Net Income | $-4,400,000 | $-3,518,000 | $-4,206,000 | $-5,822,000 | $-1,886,000 |
| Net Margin | -95.7% | -75.8% | -80.1% | -862.5% | N/A |
| EPS | $-0.13 | $-0.12 | $-0.15 | $-0.23 | $-0.08 |
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.
Visit WebsiteEarnings History & Surprises
ABNX.PAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 4, 2026 | — | — | — | — |
Q3 2025 | Sep 25, 2025 | — | $-0.07 | — | — |
Q2 2025 | May 28, 2025 | — | $-0.07 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-0.06 | — | — |
Q2 2024 | May 17, 2024 | — | $-0.04 | — | — |
Q3 2023 | Aug 17, 2023 | — | $-0.08 | — | — |
Q2 2023 | May 17, 2023 | — | $-0.06 | — | — |
Q4 2022 | Nov 18, 2022 | — | $-0.09 | — | — |
Q2 2022 | May 19, 2022 | — | $-0.13 | — | — |
Q4 2021 | Nov 4, 2021 | — | $-0.10 | — | — |
Q2 2021 | May 6, 2021 | — | $-0.04 | — | — |
Q4 2020 | Oct 22, 2020 | — | $-0.04 | — | — |
Q1 2020 | Mar 10, 2020 | — | $-0.05 | — | — |
Q3 2019 | Sep 6, 2019 | — | $0.15 | — | — |
Q2 2019 | Apr 29, 2019 | — | $-0.15 | — | — |
Q3 2018 | Sep 10, 2018 | — | $-0.19 | — | — |
Q2 2018 | Apr 19, 2018 | — | $-0.23 | — | — |
Q4 2017 | Oct 26, 2017 | — | $-0.04 | — | — |
Q1 2017 | Feb 17, 2017 | — | $-0.57 | — | — |
Q4 2016 | Nov 7, 2016 | — | $-0.76 | — | — |
Latest News
Frequently Asked Questions about ABNX.PA
What is ABNX.PA's current stock price?
What is the analyst price target for ABNX.PA?
What sector is ABIONYX Pharma S.A. in?
What is ABNX.PA's market cap?
Does ABNX.PA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ABNX.PA for comparison